AMGN vs DGX: fair value comparison
Amgen Inc. and Quest Diagnostics Incorporated · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMGN currently sits closer to the top of our ranking by discount to fair value.
| AMGN | DGX | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $414.87 | $230.97 |
| 12-month range | $291.16–$444.12 | $173.49–$247.45 |
| Rank by discount to fair value | #81 of 108 Healthcare | #82 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | High | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: AMGN fair value analysis · DGX fair value analysis